Menu

Markets

Research

News

Learn
Paper trading
AI Chat
Get the app WatchlistsPortfoliosAlerts
Sign in

Ionis Pharmaceuticals, Inc. IONS

Set alert

Price alert · IONS

All alert types
40.48 USD -0.77 -1.85%

As of Nov 3, 11:23 AM ET

Bid
40.46 × 2
Ask
40.49 × 1
40.51 Day range 41.83
40.51 52-week range 86.74
YTD
-48.84%
1 year
-45.04%
Open
41.35
Prev close
41.24
Mkt cap
6.73B
Vol
602.72K
Avg vol
3.13M
EPS
-3.48
P/E
0.00
Div yield
0.00%
More statistics
Low
40.51
High
41.83
Forward P/E
-35.98
Beta
0.40
Short ratio
5.20
Inst. own
110.24%
Dividend
0.00
Ex-div date
Earnings
Nov 4, 2026
50-d avg
49.02
200-d avg
66.79
1y target
84.13

3M chart

Chart tools
Interval
1m5m15m30m

Events in this range
  • Sep 9, 2026Rating: Barclays · Overweight → Overweight
  • Sep 15, 2026Rating: Guggenheim · Buy → Buy
  • Sep 22, 2026Rating: JP Morgan · Overweight → Overweight
  • Sep 24, 2026Rating: HC Wainwright & Co. · Buy → Buy
  • Oct 15, 2026Rating: UBS · Neutral → Buy
  • Oct 22, 2026Rating: BMO Capital · Market Perform → Outperform
Signals (7)
NameDateAgo
SMA: BearishOct 30, 20264 days ago
SMA: BullishOct 28, 20266 days ago
MACD: Buy SignalOct 2, 20261 month ago
RSI: OversoldSep 15, 20261 month ago
SMA: BearishSep 8, 20261 month ago
MACD: Sell SignalSep 4, 20262 months ago
SMA: BullishAug 17, 20262 months ago

Analyst view

Consensus: buy

Buy
Price target (mean) 84.13 +107.9% upside
Target (low)
58.00
Target (mean)
84.13
Target (high)
105.00
Ratings (0m) 25 21 buy · 4 hold · 0 sell
  • Strong buy9
  • Buy12
  • Hold4
  • Sell0
  • Strong sell0

Recommendation trend

  • This month 25
  • 1 month ago 24
  • 2 months ago 24

Earnings and revenue estimates

Consensus for the coming quarters and fiscal years

IONS analyst estimates
PeriodEPS estimateLow – highYear agoEPS growthRevenue estimateRevenue growthAnalysts
Current quarter-0.93444-1.08 – -0.65-0.6125-52.6%184.38M+17.4%9
Next quarter-0.8875-1.20 – -0.61-1.15+22.7%236.90M+16.7%8
Current year-2.62-2.99 – -2.12-1.54-70.0%922.37M-2.3%10
Next year-1.15-2.47 – 0.60-2.62+56.3%1.36B+47.4%10

Upgrades and downgrades

The latest rating changes

IONS analyst upgrades and downgrades
DateFirmActionFromTo
Oct 22, 2026BMO CapitalUpgradeMarket PerformOutperform
Oct 15, 2026UBSUpgradeNeutralBuy
Sep 24, 2026HC Wainwright & Co.ReiteratedBuyBuy
Sep 22, 2026JP MorganMaintainedOverweightOverweight
Sep 15, 2026GuggenheimMaintainedBuyBuy
Sep 9, 2026BarclaysMaintainedOverweightOverweight
Sep 8, 2026Morgan StanleyMaintainedOverweightOverweight
Sep 8, 2026Goldman SachsMaintainedNeutralNeutral
Sep 8, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Sep 8, 2026Canaccord GenuityMaintainedBuyBuy
Sep 8, 2026HC Wainwright & Co.MaintainedBuyBuy
Sep 4, 2026NeedhamReiteratedBuyBuy
Sep 4, 2026BMO CapitalMaintainedMarket PerformMarket Perform
Sep 4, 2026HC Wainwright & Co.ReiteratedBuyBuy
Aug 31, 2026HC Wainwright & Co.ReiteratedBuyBuy
Aug 19, 2026BMO CapitalInitiatedOutperformMarket Perform
Aug 3, 2026JP MorganMaintainedOverweightOverweight
Jul 30, 2026Wells FargoMaintainedOverweightOverweight
Jul 30, 2026HC Wainwright & Co.MaintainedBuyBuy
Jul 21, 2026GuggenheimMaintainedBuyBuy
Jul 16, 2026Wolfe ResearchDowngradeOutperformPeer Perform
Jul 13, 2026RBC CapitalMaintainedOutperformOutperform
Jul 10, 2026HC Wainwright & Co.MaintainedBuyBuy
Jul 10, 2026Morgan StanleyMaintainedOverweightOverweight
Jul 10, 2026BarclaysMaintainedOverweightOverweight
Jul 10, 2026Canaccord GenuityMaintainedBuyBuy
Jul 10, 2026CitigroupMaintainedBuyBuy
Jul 9, 2026JefferiesMaintainedBuyBuy
Jul 9, 2026NeedhamMaintainedBuyBuy
Jun 25, 2026Goldman SachsMaintainedNeutralNeutral